医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Genetron Health Announces Forthcoming Unveiling of Its Cancer Research Papers at the AACR Annual Meeting

2020年04月20日 PM09:00
このエントリーをはてなブックマークに追加


 

BEIJING

Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that 14 cancer research papers will be presented as posters at the American Association for Cancer Research (AACR) 2020 Annual Meeting, which will take place virtually on April 27-28 and June 22-24.

In collaboration with over 10 notable cancer research centers and clinical hospitals in China, including the Chinese PLA General Hospital (301 Hospital), Cancer Hospital of Chinese Academy of Medical Sciences, Beijing Tiantan Hospital of Capital Medical University, Genetron Health’s presentation will cover a broad spectrum of precision oncology topics such as molecular and immunological diagnostics, bio-informatics analysis in multiple cancer types including lung cancer, gastric cancer, central nervous system tumors and urinary system tumors.

Scientists at Genetron Health with a multi-disciplinary background have devoted significant resources to continuously optimize key diagnostics technologies including liquid biopsy, fusion detection, and algorithms for bioinformatics. They focus on improving the quality and efficiency of sample testing, as well as the comprehensiveness and stability of bioinformatics analysis. Genetron Health has accumulated clinically valuable data in the fields of diagnostics, neoadjuvant chemotherapy prognosis and efficacy evaluation, immunotherapy, and drug resistance to facilitate translation into clinical applications.

Genetron Health actively collaborates with clinicians to drive cancer genomics research. The Company has published over 20 papers in Nature Genetics, Cancer Cell, Nature Communications, PNAS, and other internationally recognized academic journals, accelerating the clinical translation and commercialization of scientific research and continously improving the reliability and accessibility of its products and technology. Genetron Health is committed to making available advanced and reliable precision medicine technology to the community.

About the AACR

Founded in 1907, the American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. It has grown from its earliest 11 members to over 47,000 members in 127 countries and territories. The mission of AACR is to prevent and cure cancer through research, education, communication and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.The AACR Annual Meeting is one of the largest cancer research conferences in the world, attracting nearly 20,000 professionals from across the globe each year.

About Genetron Health

Genetron Health is a leading and fast-growing precision oncology company in China that aims to provide one-stop genomic profiling solutions for multiple scenarios covering early screening, diagnosis and monitoring, and biopharmaceutical services. The company collaborates with over 400 hospitals and dozens of biopharmaceutical companies and research institutions, and has developed a large proprietary genomic database.

Genetron Health has established R&D centers in both the United States and China, two manufacturing facilities with both ISO 13485:2016 certification and ISO 9001 2015 certification in China and five clinical laboratories in Beijing (CLIA accreditation and CAP certification), Shanghai, Hangzhou, Chongqing and Guangzhou. The R&D capacities of Genetron Health are supported by a best-in-class research and development team led by scientists at the forefront of cancer genomics research. The company has published many research papers in highly influential worldwide peer-reviewed scientific journals, such as Nature Genetics, Nature Communications, Cell Research and PNAS. For more information, please visit www.genetronhealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200420005389/en/

CONTACT

For media inquiries, please contact:

Tao Yuan

E-mail: pr@genetronhealth.com

同じカテゴリーの記事 

  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China
  • Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
  • エクセルゲン、バクスター・インターナショナルを提訴。口腔体温計の精度に関するデータの公表権を擁護
  • パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携